114 related articles for article (PubMed ID: 10456444)
1. The 536C-->T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis.
Kleesiek K; Schmidt M; Götting C; Schwenz B; Lange S; Müller-Berghaus G; Brinkmann T; Prohaska W
Thromb Haemost; 1999 Jul; 82(1):1-5. PubMed ID: 10456444
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden.
Lincz LF; Adams MJ; Scorgie FE; Thom J; Baker RI; Seldon M
Blood Coagul Fibrinolysis; 2007 Sep; 18(6):559-64. PubMed ID: 17762532
[TBL] [Abstract][Full Text] [Related]
3. Analysis of a T-287C polymorphism in the tissue factor pathway inhibitor gene and identification of a repressor element in the promoter.
Amini Nekoo A; Iles D
Thromb Res; 2008; 121(6):813-9. PubMed ID: 17931693
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy.
Opstad TB; Eilertsen AL; Høibraaten E; Skretting G; Sandset PM
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):516-21. PubMed ID: 20453636
[TBL] [Abstract][Full Text] [Related]
5. The TFPI 536C-->T mutation is not associated with increased risk for venous or arterial thrombosis.
González-Conejero R; Lozano ML; Corral J; Martínez C; Vicente V
Thromb Haemost; 2000 May; 83(5):787-8. PubMed ID: 10823280
[No Abstract] [Full Text] [Related]
6. The C536T transition in the tissue factor pathway inhibitor (TFPI) gene does not contribute to risk of venous thrombosis among carriers of factor V Leiden.
Hessner MJ; Luhm RA
Thromb Haemost; 2000 Oct; 84(4):724-5. PubMed ID: 11057878
[No Abstract] [Full Text] [Related]
7. Association of Asn221Ser mutation in tissue factor pathway inhibitor-beta with plasma total tissue factor pathway inhibitor level.
Ishikawa J; Okada H; Kato H; Takeshita S; Honda S; Kawasaki T; Suehisa E; Tsuji H; Madoiwa S; Sakata Y; Kojima T; Murata M; Ikeda Y; Kokubo Y; Okamura T; Tomoike H; Miyata T
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):22-6. PubMed ID: 20523161
[TBL] [Abstract][Full Text] [Related]
8. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.
Ariëns RA; Alberio G; Moia M; Mannucci PM
Thromb Haemost; 1999 Feb; 81(2):203-7. PubMed ID: 10063992
[TBL] [Abstract][Full Text] [Related]
9. The -33T-->C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations.
Ameziane N; Seguin C; Borgel D; Fumeron F; Moatti D; Alhenc-Gelas M; Grandchamp B; Aiach M; Emmerich J; de Prost D
Thromb Haemost; 2002 Aug; 88(2):195-9. PubMed ID: 12195688
[TBL] [Abstract][Full Text] [Related]
10. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of the C536T mutation in the tissue factor pathway inhibitor (TFPI) gene among patients with venous thromboembolic disease.
Paciaroni K; Rossi E; Bazzan M; Ireland H; De Stefano V
Thromb Haemost; 2001 May; 85(5):938-9. PubMed ID: 11372693
[No Abstract] [Full Text] [Related]
12. One novel and one recurrent mutation in the PROS1 gene cause type I protein S deficiency in patients with pulmonary embolism associated with deep vein thrombosis.
Mizukami K; Nakabayashi T; Naitoh S; Takeda M; Tarumi T; Mizoguchi I; Ieko M; Koike T
Am J Hematol; 2006 Oct; 81(10):787-97. PubMed ID: 16868938
[TBL] [Abstract][Full Text] [Related]
13. Tissue factor pathway inhibitor gene disruption.
Broze GJ
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S89-92. PubMed ID: 9819035
[TBL] [Abstract][Full Text] [Related]
14. Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis.
Sidelmann JJ; Bladbjerg EM; Gram J; Münster AM; Jespersen J
Blood Coagul Fibrinolysis; 2008 Jul; 19(5):405-9. PubMed ID: 18600090
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in the protein C gene as risk factor for venous thrombosis.
Pomp ER; Doggen CJ; Vos HL; Reitsma PH; Rosendaal FR
Thromb Haemost; 2009 Jan; 101(1):62-7. PubMed ID: 19132190
[TBL] [Abstract][Full Text] [Related]
16. [Tissue factor pathway inhibitor (TFPI) and its role in pathology].
Rucińska M; Gacko M; Skrzydlewski Z
Postepy Hig Med Dosw; 1997; 51(4):421-30. PubMed ID: 9446103
[TBL] [Abstract][Full Text] [Related]
17. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
[TBL] [Abstract][Full Text] [Related]
19. Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state.
Dahm A; Rosendaal FR; Andersen TO; Sandset PM
Br J Haematol; 2006 Feb; 132(3):333-8. PubMed ID: 16409298
[TBL] [Abstract][Full Text] [Related]
20. Analysis of sequence variations in the promoter region of the human tissue factor pathway inhibitor 2 gene in apoplectic patients and blood donors.
Siegling S; Thyzel E; Glahn J; Kleesiek K; Götting C
Ann Hematol; 2006 Jan; 85(1):32-7. PubMed ID: 16247609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
